We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Makers of Zoloft (sertraline hydrochloride) and its generic versions are reporting shortages linked to increased demand during the pandemic coupled with supply chain issues caused by the impact of COVID-19 on manufacturers of active pharmaceutical ingredients (APIs). Read More
The agreement will begin immediately to address Moderna's increasing demand over the upcoming months and will focus on securing future long-term supply. Read More
The agreement builds upon a previous deal that AstraZeneca and the University of Oxford entered into last month, under which the company is responsible for manufacturing the vaccine. Read More
GlaxoSmithKline (GSK) said it plans to manufacture 1 billion doses of its vaccine adjuvant next year to support multiple COVID-19 vaccine candidates. Read More
Maryland-based Novavax is expanding its manufacturing capacity for its COVID-19 vaccine candidate by acquiring a manufacturer in the Czech Republic as drugmakers rush to prepare for the global deployment of a successful vaccine. Read More
Bangladesh-based Beximco Pharmaceuticals has become the first company to launch a generic version of Gilead Sciences’ remdesivir for treating COVID-19. Read More
TriNetX is partnering with the FDA’s Sentinel Operations Center at the Harvard Pilgrim Health Care Institute (HPHCI) to monitor priority drugs used for treating hospitalized COVID-19 patients. Read More
In a surprise move, HHS has awarded a new Virginia-based company a $354 million contract to produce active pharmaceutical ingredients (APIs) and finished drugs to create a new Strategic Active Pharmaceutical Ingredients Reserve. Read More